CervoMed Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	9.31	9.74	7.14	-	-
Revenue Growth (YoY)	15.14%	36.29%	-	-	-
Cost of Revenue	18.8	18.8	8.44	1.34	-
Gross Profit	-9.49	-9.06	-1.29	-1.34	-
Selling, General & Admin	9.42	9.17	6.52	2.14	2.62
Research & Development	2.02	-	-	-	2.42
Operating Expenses	11.44	9.17	6.52	2.14	5.04
Operating Income	-20.94	-18.23	-7.81	-3.48	-5.04
Interest Expense	-	-	-	-0	-0
Interest & Investment Income	2.27	1.94	0.22	0.06	0.02
Other Non Operating Income (Expenses)	-0	-0	5.42	-2.39	0.74
EBT Excluding Unusual Items	-18.67	-16.29	-2.17	-5.8	-4.28
Other Unusual Items	-	-	-	-	0.15
Pretax Income	-18.67	-16.29	-2.17	-5.8	-4.14
Net Income	-18.67	-16.29	-2.17	-5.8	-4.14
Net Income to Common	-18.67	-16.29	-2.17	-5.8	-4.14
Shares Outstanding (Basic)	9	8	3	1	5
Shares Outstanding (Diluted)	9	8	3	1	5
Shares Change (YoY)	113.67%	203.34%	413.65%	-88.49%	-
EPS (Basic)	-2.14	-2.02	-0.82	-11.20	-0.92
EPS (Diluted)	-2.14	-2.02	-0.82	-11.20	-0.92
Gross Margin	-101.95%	-93.04%	-18.11%	-	-
Operating Margin	-224.91%	-187.18%	-109.35%	-	-
Profit Margin	-200.58%	-167.29%	-30.40%	-	-
EBIT	-20.94	-18.23	-7.81	-3.48	-5.04
EBIT Margin	-224.91%	-187.18%	-109.35%	-	-

Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q